Lucrecia Marquez-Rosado, M.D., Ph.D., is a physician-scientist with over 20 years of experience in oncology, immunology, and drug discovery in both academia and biotech. She completed her clinical training at the Salvador Zubirán National Institute, earned her Ph.D. in Cell Biology from CINVESTAV, and finished a postdoctoral fellowship at the Fred Hutchinson Cancer Research Center. Before co-founding LuMiAL Bio, she held scientific roles at Boehringer Ingelheim, SIBTECH, and Nurix Therapeutics, where she led cross-functional teams involved in translational research programs.
Lucrecia expertise includes Novel Therapeutic Modalities, biomarkers and disease-positioning strategies, focuses on translating innovative science into clinically actionable oncology programs.
Ann Mongan is a Subject Matter Expert in translational research and biomarker development, with her most recent role being Executive Director of Translational Research at Bristol Myers Squibb. With nearly two decades of experience, she has worked on more than 10 drugs (including ibrutinib and mezigdomide), from IND through all phases of development. Her experience spans multiple therapeutic areas, including oncology, neuroscience, and autoimmune diseases, and includes work at both large companies (BMS, AbbVie, Amgen) and small companies (Annexon). She received a PhD in Bioinformatics from UC San Diego and is also an expert in AI/ML and the integration of generative AI applications into science.
Saurabh is an experienced scientific leader with 20+ years of cross-disciplinary R&D experience across Bristol Myers Squibb, Arsenal Biosciences, and Sana Biotechnology, spanning drug discovery and translational research. He has deep expertise in precision medicine, biomarker strategy and assay development, multi-omics technologies, and functional genomics.
As a Senior Director at Arsenal Biosciences, Saurabh led teams developing AI foundation models for Immunology, IND-enabling genotoxicity assays, and molecular assays for translational PK/PD biomarkers. At Bristol Myers Squibb, he led the application of multi-omics, functional genomics, and Precision Discovery & Medicine approaches across Oncology, Immunology, Cardiovascular, and Neuroscience programs.
Previously, he led cross-functional teams at Sana Biotechnology and GenapSys, and was co-founder of Euveda Biosciences. Saurabh completed his Ph.D. and postdoctoral training at Johns Hopkins University.
For financial institutions, the “gold rush” of AI experimentation is meeting the “brick wall” of the EU AI Act. As organizations move from internal pilots to customer-facing production, the critical question is no longer just about model accuracy – it’s about Governance. How do you track every prompt, redact PII in real-time, and manage skyrocketing token costs without slowing down your developers?
In this session, SEB and Kong share a blueprint for leveraging a dedicated AI Gateway – a centralized “control plane” that decouples AI innovation from regulatory complexity.
Lidia Treiber, CFA®, is a globally experienced investment professional, author, and Non-Executive Director with expertise spanning traditional and alternative investments. She has worked at leading asset managers, including BlackRock, Wellington, Invesco, and WisdomTree, contributing to the growth of their international investment businesses and sharing investment insights with institutional investors, wealth managers, and family offices to support informed decision-making.
She has been featured in the Financial Times, on CNBC, and in leading European publications and is known for translating complex financial concepts into clear, practical insights. As a CFA charterholder with credentials in sustainable investing, she combines technical expertise with a deeply human approach to wealth.
Drawing on her international career across the US, UK, and Europe, Lidia is passionate about empowering others to engage confidently with wealth management. Through her new book Build Out Wealth, and speaking engagements, she demystifies investing and helps professionals align financial success with long-term purpose and values.
Jakob Skovgaard is the Co‑Founder and CEO of PlanetDairy, where he leads the development of innovative hybrid dairy products that blend traditional dairy with modern, sustainable technologies. His work positions PlanetDairy at the forefront of transforming the dairy industry with solutions that reduce environmental impact while maintaining taste and quality.
